13-05-2025 20:08 via medpagetoday.com

CVS Drops Obesity Drug; Once-Weekly Growth Hormone; WeightWatchers' Bankruptcy

(MedPage Today) -- Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor of semaglutide (Wegovy), despite the latter yielding less weight loss. (New York Times)
Transmasculine...
Read more »

Medical news



Biden Wheelchair Bombshell; Rethinking Race-Based Scholarships; Toxic Booze Kills 14
Sedentary Time Tied to Brain Volume, Worse Cognition in Older Adults
Expect More Downside Risk in Medicare's Payment Models, CMS Official Says
Better Survival in BRCA-Mutated Breast Cancer With Neoadjuvant Olaparib-Chemo Combo
Doctors, Other Healthcare Workers Strike in Washington State
HIV Drugs and Alzheimer's; Duchenne Drug Shows Benefit; PFAS and Cognitive Changes
Low LDL and Bleeding Risk; Improved HoFH Life Expectancy; ANGPTL4 mAb Progress
FDA, RFK Jr. Aim to Remove Ingestible Fluoride Products Used to Protect Kids' Teeth
Would You Recognize the Signs of Trafficking in a Patient?
Late Abortions Are Rare. The U.S. Just Lost a Clinic That Performed Them Since 1973.
Polarized and Politicized: Can We Find Middle Ground in Youth Gender Care?
Global Progress Continues on Reducing Rotavirus Burden, With Caveats
USPSTF Reaffirms Universal Syphilis Screening in Pregnancy
Pfizer Confirms: Leading JAK Inhibitor Often Comes With Weight Gain
Desktop versie